Kelun Pharmaceutical
Country/Region: Hong Kong, S.A.R., China
Founded in 1996, Kelun has developed into a highly specialized innovative pharmaceutical group with annual sales revenue of over RMB 40 billion, including more than 100 enterprises at home and abroad, such as Sichuan Kelun Pharmaceutical, Hunan Kelun Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute, Klus Pharma (Kelun, USA), Kelun-Kazpharm (Kelun, Kazakhstan), and Kelun Lifesciences (Kelun, Sri Lanka), etc. In 2017, Kelun ranked 155th in China's top 500 manufacturing enterprises. In 2018, Kelun was awarded as the Single Champion Demonstration Enterprise of National Manufacturing Industry of IV solutions in China. In 2022, Kelun ranked among the top 3 in Chinese pharmaceutical manufacturing industry.
Kelun Pharmaceutical was listed on the Shenzhen Stock Exchange (Stock Code: 002422, KELUN PHARMA) in June 2010. At the same time, Kelun immediately launched the plan of RMB 10 billion industrial investment and began to implement the development strategy of "three development driving engines and innovative
growth". The first engine is through continuous industrial upgrading and product variety adjustment, to maintain Kelun's absolute leading position in the field of IV solutions. The second engine is to build the competitive advantage of the whole antibiotic industrial chain from intermediates, APIs to FPPs by innovative development and utilization of quality natural resources. The third engine is to accumulate the ultimate driving force for the enterprise development through the construction of research and development system and diversified technological innovation. By implementing the development strategy, another two listed companies are born in Kelun. In December 2022, Chuanning Biotechnology successfully went listed on the Shenzhen Stock Exchange GEM (Growth Enterprise Market) (Stock Code: 301301, CN BIO). In July 2023, Kelun-Biotech was successfully listed on the Hong Kong Stock Exchange (Stock Code: 06990, SKB BIO), marking the start of a new journey for Kelun's innovative research and development and its global layout.
Innovation is the spirit of enterprise competition. Kelun sticks to investing at least 10% of annual sales revenue in innovation every year and has made the most of medical research talents and other competitive resources at home and abroad. The company established an R&D system with multiple technical categories and a fully functional platform, which includes the Chengdu and Suzhou Research Institutes as the main body committed to high-end generics while Kelun-Biotech and Klus Pharma (the U.S. branch) as the main body focused on innovation research. This is a new kind of R&D mode fully in line with international standards.
Kelun has established the National Postdoctoral Scientific Research Workstation and Academician Workstation. In 2022, Kelun-Biotech was approved by the National Development and Reform Commission to establish the "National Engineering Research Center of Targeted Biologics". As of now, Kelun has applied for more than 4,000 patents, wherein over 2,000 patents got licensed. Moreover, Kelun has also launched research into the development of more than 500 critical drugs among multifields, such as tumors, bacterial infection, parenteral nutrition, etc. Since 2017, more than 20 items have been approved for going onto the market annually. Kelun has gradually entered a virtuous cycle of R&D input and output. At the same time, nearly 20 first-in-class innovative drugs of the company have successively entered the stage of clinical research and production application.
E-mail
E-Meeting